This is a diagnostic pilot study that recruited 25 normal volunteers and 40 patients with dysfunctional brain diseases and performed 18F-DPA-714 PET/MR imaging to evaluate the correlation between the multimodal imaging features of dysfunctional brain diseases, to explore the potential pathological mechanisms of neuroimmune activation, and to further analyse the value of PET/MR-based multimodal imaging in the diagnosis and differential diagnosis of dysfunctional brain diseases. and further analyse the diagnostic and differential diagnostic value of PET/MR-based multimodal imaging in dysfunctional brain diseases.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
65
Saline intravenous solution of 18F-DPA-714 administered at 0.1 mCi/kg by bodyweight
Maximum Standardized uptake value (SUVmax)
Time frame: 1 day from injection of the tracer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.